• Contact Us
TriSalus Life Sciences
  • Our Story
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Boards
  • Our Passion
  • Our Approach
    • Multi-Pronged Approach
    • Immunomodulation
      • Toll-Like Receptor 9 Agonist
    • Drug Delivery
    • Our Products
  • Our Therapeutic Pipeline
    • Pipeline Overview
    • Product Candidates
      • SD-101
    • Clinical Trials for Healthcare Professionals
    • Scientific Publications & Presentations
  • Patients & Caregivers
    • Patients
    • Our Team Approach
    • Clinical Trials for Patients
    • Patient Resources
  • News & Events
    • News
    • Events
Select Page

Abstract No. 133 Surefire Infusion System (SIS) hepatocellular carcinoma registry study interim results: a multicenter study of the safety, feasibility, and outcomes of the SIS expandable-tip microcatheter in DEB-TACE

by Peter R | Apr 1, 2018 | Drug Delivery, Publications and Presentations

Our Story Our Passion Our Approach Our Therapeutic Pipeline Patients & Caregivers News Events

TriSalus Life Sciences
6272 W. 91st Avenue
Westminster, CO 80031

   

© 2021 TriSalus™    All Rights Reserved   Privacy Policy   Compliance    Terms of Use

You are now leaving the TriSalus Life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus' standards.

Third Party Sites
TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of TriSalus or this website.

Thank you for visiting our site.